Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Slides:

Advertisements

Similar presentations

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Advertisements

Diabetes Mellitus Type 2

Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.

Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.

ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.

Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University

Blood glucose: is lower better for diabetic patients?

Diagnosis of diabetes. Diabetic symptoms Diabetic symptoms + venous sample for : –Random venous ≥ 11.1 mmol/l ( ) –Fasting glucose > 7(

Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.

Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.

1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.

Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

Glycemic Control: When the Lower is Not the “Better”?

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

1 Part 1 Importance of Identifying and Managing Postprandial Hyperglycemia An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Prevalence (%) estimates of diabetes (20-79 years) 2010.

Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.

Carina Signori, D.O., M.P.H. Penn State Hershey Medical Center Ceriello, Antonio. Diabetes Care August 2010;33,8.

R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus

Insulin Delivery Systems Atlanta Diabetes Associates

Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM

Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.

HOPE: Heart Outcomes Prevention Evaluation study

Heart Health & Diabetes

Diabetes and Risk of CV Outcomes

Panelists. Type 2 Diabetes, Renal Impairment, and CHD: Reducing 2 Vascular Risks With 1 Stone.

Macrovascular Complications Microvascular Complications

New Insights on PPAR Agonists For Cardiovascular Disease

New Patient-Friendly Options for Managing Insulin Dosing

366 میلیون نفر در جهان مبتلا به دیابت هستند.

The following slides highlight an educational report based on a Satellite Symposium presentation at the 2008 Canadian Cardiovascular Congress in Toronto.

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Recurrent Angina: New Tools for an Old Problem

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Impacting CV Risk With Diabetes Medications

Impacting CV Risk With Diabetes Medications

Panelists. Secondary Prevention of Macrovascular Events in Type 2 Diabetes: Focus on Dyslipidemia.

Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes

Statins and Glucose Metabolism: Are All Agents Alike?

UKPDS 34: Metformin vs Conventional Glycemic Control on Outcomes

Growing Diabetes Pandemic Worldwide

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

UKPDS 35: Impact of Increasing A1c on Cardiovascular Disease in T2DM

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Diabetes and Cardiovascular Disease Risk: The Hard Truth

The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.

Diabetes Journal Club March 17, 2011

Diabetes and Cardiovascular Disease Risk: The Hard Truth

Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials Sanjay Rajagopalan Journal of Indian College.

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Oral Combination Therapy for T2D

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Pharmacotherapy for Diabetic Coronary Disease:

2015 EASD In Review: CV Risk management in t2dm

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

PowerPoint 16:9 Screen Ratio Template *

Presentation transcript:

How Should Cardiologists Manage Glycemia More Actively in Their Patients With Diabetes?

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

UKPDS 35: Effect of HbA1c on MI and Microvascular Events

UKPDS 35: Impact of Increasing HbA1c on Cardiovascular Disease in T2D

Effect of Intensive Glucose Control on All-Cause Mortality

Effect of Intensive Glucose Control on Major Cardiovascular Events

Goals for CV Prevention in T2D

Oral Antihyperglycemic Medications: Effect on HbA1c

Antihyperglycemic Medications: Glycemic Action and Possible Side Effects

Glucose Control in Patients With ACS

Incidence of Type 2 Diabetes or Impaired Glucose Tolerance in Patients With ACS

Summary